China's Secret NeuroTech Boom: The BCI Startups the West Isn't Talking About
While Neuralink commands most of the global headlines, a parallel BCI industry with its own unicorns, government backing, and clinical firsts is quietly scaling in China — and the gap is closing fast.
Elon Musk gets the press. Nine patients, a surgical robot, and a PR machine that makes every trial feel like a moonshot. Meanwhile, on the other side of the planet, a 30-year-old NeuroXess co-founder named Tiger Tao is quietly letting patients play video games with their minds, a quadriplegic man in Shanghai is steering a wheelchair outdoors using only his thoughts, and a company called BrainCo just completed the second-largest BCI financing round in global history, trailing only Neuralink itself. China’s BCI sector raised over 5 billion yuan (roughly $700 million) in financing rounds in 2025 alone, according to VCBeat’s tracking. The silence from Western media is not because nothing is happening. It’s because the story is harder to tell from a distance, and the companies involved rarely show up at SXSW.
China’s BCI industry is not just a “catching-up” story. That framing is lazy and increasingly inaccurate. In March 2026, China became the first country in the world to approve an invasive BCI device for commercial use — a coin-sized wireless implant by Shanghai-based Neuracle Medical Technology, designed for patients with spinal cord injuries. First in the world. Not a trial. Not an exemption. A commercial product you can prescribe. The US still hasn’t done that. This detail somehow failed to generate the breathless coverage it deserves. If Neuralink had done it, every tech outlet in the Western hemisphere would have led with it for a week.
The pieces of what’s happening in China — the startups, the government infrastructure, the clinical milestones, the funding rounds, the national roadmaps — don’t get assembled into a coherent picture often enough. This is an attempt to fix that.
The companies you should actually know
China has an estimated 170+ BCI companies operating as of 2024, according to CCID Consulting data cited in BioSpectrum Asia. Most of those are small. A handful matter enormously. 🧠
NeuroXess is arguably the most technically ambitious of the lot. Founded in 2021 — yes, just five years ago — by the same Phoenix Peng who later founded ultrasound BCI startup Gestala, NeuroXess specializes in flexible, high-channel implantable electrodes. The company made global headlines when it worked with Huashan Hospital and the Tianqiao and Chrissy Chen Institute to decode a patient’s thoughts into Chinese text in real time — delivering what researchers called the world’s first New Year’s greeting sent entirely via thought. “2025 Happy New Year,” composed in a patient’s mind, appeared on a screen and commanded a robotic arm to make a heart gesture. That’s not a stunt. That’s clinical language decoding in a human patient. In April 2025, NeuroXess disclosed a separate collaborative project implanting a 256-channel flexible BCI in an epilepsy patient that enabled complex video game control — another milestone in the same 12-month window.
StairMed Technology is building toward the most aggressive clinical timeline in the Chinese invasive BCI field. The Shanghai company raised $48 million in a Series B in February 2025, then followed up with another $72.8 million in April 2026, bringing its total fundraising to over RMB 1.1 billion (~$160 million) in under a year. That’s a fundraising pace that would be remarkable anywhere in the world. StairMed’s implant uses a 3-to-5 millimeter cranial puncture to place its sensor 5-8 millimeters into the brain — a design the company says reduces foreign-body sensation while preserving signal quality. The company is now planning large-scale multicenter registration trials targeting 40 patients in 2026, with formal clinical trials expected in 2027. Tencent is a core investor. Alibaba and SDIC Unity Capital joined the most recent round. When a BCI startup has two of China’s biggest tech conglomerates on its cap table, it is not a research curiosity. It is a product pipeline.
BrainCo operates at a different layer entirely — the consumer and medical device intersection. Founded in 2015 at the Harvard Innovation Lab by Han Bicheng, the Hangzhou company has pushed consumer-oriented brain devices to 100,000 units and just completed a CNY 2 billion ($286 million) financing round, the largest BCI investment globally outside of Neuralink. BrainCo has quietly filed for a Hong Kong IPO, and in January 2026 it received approval for its FocusJoy medical edition — an EEG-based ADHD intervention product for children. That’s a regulated medical device for pediatric attention disorders, already approved, already in the Chinese market.
Other names worth tracking:
NeuCyber Neurotech, a Beijing Institute for Brain Research startup with its Beinao-1 semi-invasive chip, which has completed seven human implantations and aims to expand trials to 50 patients
Neuracle Medical Technology, the first company anywhere in the world to receive commercial approval for an invasive BCI, a point worth repeating 📈
Gestala, Phoenix Peng’s second company, which raised $21 million in March 2026 for ultrasound-based non-invasive BCI — a potential next-generation modality that avoids the limitations of both EEG and implants
What’s your read on this field — are Western neurotech investors underestimating China’s BCI ecosystem, or is the technical gap still wide enough that the US companies maintain a meaningful lead?
The policy machine that built this
This didn’t happen organically. China’s BCI acceleration is not a story of scrappy entrepreneurs defying institutional inertia — it is institutional. The government didn’t just notice BCI and issue a supportive white paper. It built a supply chain strategy, coordinated seven ministries, tied funding to specific technical milestones, and connected regulatory approval directly to national insurance reimbursement. 🔬
The Georgetown Center for Security and Emerging Technology has documented China’s key 2025 BCI policy directive in detail: in August 2025, the Ministry of Industry and Information Technology joined six other central agencies to release the Implementation Opinions on Promoting Innovation and Development of the Brain-Computer Interface Industry. Seven ministries. One coordinated document. The goals are specific and timed:
By 2027: achieve international-level performance in BCI electrodes, chips, and integrated systems; complete clinical trials on two to three flagship products; create three to five unicorn-status companies
By 2030: establish a full domestic BCI supply chain; produce two to three “world-class” BCI enterprises; bring invasive BCI to commercial scale
The December 2025 Shenzhen BCI Expo added 11.6 billion yuan ($165 million) in a dedicated brain science fund to support companies across the research-to-commercialization pipeline. Shanghai’s municipal government separately released a 2025–2030 BCI action plan in January 2025. Sichuan province published its own roadmap the following May. Guangdong, which now hosts approximately 80 key BCI enterprises, issued its own cultivation plan in 2024. These are not overlapping bureaucratic documents. They are coordinated policy layers at national, provincial, and municipal levels, all moving in the same direction at once.
The funding point is actually the less important innovation here. The more consequential structural difference between China’s BCI policy environment and the US one comes down to insurance reimbursement. Phoenix Peng, in a detailed TechCrunch interview from February 2026, explained the asymmetry precisely: in China, once the state approves a device, national health insurance covers it across the country essentially simultaneously. In the US, FDA approval is just the beginning — then each private insurer must individually decide whether to cover a device, a process that can take years and still produce inconsistent results. The IpsiHand BCI for stroke rehabilitation is a perfect example: FDA-cleared in 2021, it only got its first Medicare billing code in 2024, and major private insurers still classify it as investigational. In China, the regulatory-to-reimbursement pipeline runs faster by design. That’s not a criticism of the US system; it’s an observation about competitive dynamics with real consequences for which market these companies prioritize first.
The national BCI standard Medical Device Terminology for BCI Technology (YY/T 1987-2025) entered enforcement on January 1, 2026, giving China’s regulator a legal foundation to put BCI devices on a “regulatory fast track.” These are not vague aspirational documents. They are the architecture of a commercialization machine. 🚀
What the gap actually looks like — honest version
Here’s where the picture deserves some precision. China’s BCI ecosystem is real, fast-growing, and increasingly competitive. It is not technically ahead of the US across the board, and the most credible voices in the Chinese BCI field say so directly.
Li Yuan, rotating CEO of NeuCyber, told Reuters in March 2026 that the company’s frontier Beinao-2 product — its fully invasive system with flexible electrodes — is still roughly three years behind Neuralink. Neuralink has over 20 patients in active trials. Beinao-2 is still in large-scale animal testing. That is a concrete, honest self-assessment, and the gap it describes is real.
The places China is genuinely competitive, or even ahead: 🔬
Semi-invasive and flexible electrode designs: Chinese teams at NeuroXess and CAS have advanced the engineering of thin, biocompatible electrode arrays that may cause less chronic tissue response than stiffer devices
Clinical trial volume: with over 50 flexible implantable BCI trials completed by mid-2025 across Chinese hospitals, and a patient pool that is larger and more accessible than in the US, China may accumulate clinical data faster than any other country
Commercial approval speed: Neuracle’s commercial approval — the first in the world for any invasive BCI — is a regulatory milestone that the US has not yet matched, and it signals that China’s NMPA is prepared to approve these devices while US counterparts are still working through the framework
Non-invasive consumer scale: BrainCo has shipped consumer devices at a scale Western companies haven’t approached, providing a platform for real-world data accumulation
CNN’s reporting in July 2025 captures the nuance well: US researchers who have reviewed Chinese BCI research describe it as “comparable with that of other scientifically advanced nations” on the non-invasive side, while the invasive work has “picked up pace and is approaching global standards.” The word “approaching” is accurate. Not there yet. Closing fast.
The more complicated question is what the competitive frame even means here. Are we watching two countries race to help paralyzed patients communicate? Or are we watching a geopolitical contest over which country controls the architecture of human-computer interfaces? Probably both, uncomfortably. The US Senate Commerce Committee raised explicit concerns in April 2025 about neural data security and the possibility of Chinese companies using BCI data in ways that implicate national security. UNESCO adopted its first global neurotechnology ethics framework in late 2025. These are real questions. They complicate the straightforward “which country wins” framing, because what winning means for invasive BCI depends heavily on who controls the data that flows through these devices.
Why this matters for the global neurotech arc
The significance of what China is building isn’t just competitive — it’s structural. 💡 If you believe BCI is going to be a major medical and eventually consumer technology in the 2030s, then where the clinical evidence gets generated, where the devices get manufactured, and where the regulatory standards get written matters enormously.
As NeurotechMag has already noted in tracking these signals, high government involvement in neurotech usually means a technology has moved beyond niche research into territory with real economic and societal stakes. The same pattern played out in electric vehicles and solar panels, where China’s industrial policy approach created cost structures and production scales that eventually reshaped the global market. Whether BCI follows that trajectory depends on factors that aren’t fully visible yet — signal quality, biocompatibility at scale, long-term electrode stability, and the still-unsolved question of whether any implantable device works reliably enough for a mainstream clinical population. But the preconditions for that trajectory are being assembled rapidly.
Phoenix Peng’s framing at Gestala is probably the most honest articulation of where this is heading: “China offers large-scale clinical research capacity and efficient supply chains, while the U.S. has world-class scientific talent,” he told TechCrunch. He still hopes for collaboration, despite the geopolitical headwinds. That framing — two complementary strengths, better together — is more useful than a pure zero-sum race narrative. But collaboration requires trust, and trust in neurotechnology is a particularly complicated thing to build when the underlying product is a device that reads your brain.
The projection from CCID Consulting puts China’s BCI market at RMB 5.58 billion (~$780 million) by 2027, growing at 20% annually. Some projections go as high as 120 billion yuan by 2040 under optimistic scenarios. Whether those figures land precisely isn’t the point. The point is that a sector with those projections, backed by seven ministries, with a commercial device already approved and an IPO-ready company in BrainCo, is not a “watch this space” story anymore. It is already a story.
The question for anyone tracking this industry: if Neuracle’s commercial BCI approval in March 2026 — a genuine world first — barely registered in Western neurotech coverage, what else are we missing?